Dr. Oliver Weigert

10 Major publications related to project

(See publications for recent papers published in the SFB context since 2016)

Pastore A, Jurinovic V, Kridel R, Hoster E, Staiger AM, Szczepanowski M, Pott C, Kopp N, Murakami M, Horn H, Leich E, Moccia AA, Mottok A, Sunkavalli A, van Hummelen P, Ducar M, Ennishi D, Shulha HP, Hother C, Connors JM, Sehn LH, Dreyling M, Neuberg D, Möller P, Feller AC, Hansmann ML, Stein H, Rosenwald A, Ott G, Klapper W, Unterhalt M, Hiddemann W, Gascoyne RD, Weinstock DM and Weigert O (2015). Integration of Gene Mutations Improves Risk Prognostication in Patients Receiving First-line Immunochemotherapy for Follicular Lymphoma in Clinical Trial and Population-Based Cohorts. The Lancet Oncology (in print)

Odejide O*, Weigert O*, Lane AA, Toscano D, Lunning MA, Kopp N, Kim S, van Bodegom D, Bolla S, Schatz JH, Teruya-Feldstein J, Hochberg E, Louissaint A, Dorfman D, Stevenson K, Rodig SJ, Piccaluga PP, Jacobsen E, Pileri SA, Harris NL, Ferrero S, Inghirami G, Horwitz SM and Weinstock DM (2014). A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood, 123, 1293-1296. (*equal contribution)

Yoda A, Adelmant G, Tamburini J, Chapuy B, Shindoh N, Yoda Y, Weigert O, Kopp N, Wu SC, Kim SS, Liu H, Tivey T, Christie AL, Elpek KG, Card J, Gritsman K, Gotlib J, Deininger MW, Makishima H, Turley SJ, Javidi-Sharifi N, Maciejewski JP, Jaiswal S, Ebert BL, Rodig SJ, Tyner JW, Marto JA, Weinstock DM and Lane AA (2014). Mutations in G protein β subunits promote transformation and kinase inhibitor resistance. Nature Medicine, 21, 71-5.

Dutta C, Day T, Kopp N, van Bodegom D, Davids MS, Ryan J, Bird L, Kommajosyula N, Weigert O, Yoda A, Fung H, Brown JR, Shapiro GI, Letai A and Weinstock DM (2012). BCL2 Suppresses PARP1 Function and Nonapoptotic Cell Death. Cancer Research, 72, 4193-4203.

van Bodegom D, Zhong J, Kopp N, Dutta C, Kim MS, Bird L, Weigert O, Tyner J, Pandey A, Yoda A and Weinstock DM (2012). Differences in signaling through the B-cell leukemia oncoprotein CRLF2 in response to TSLP and through mutant JAK2. Blood, 120, 2853-2863.

Weigert O, Kopp N, Lane AA, Yoda A, Dahlberg SE, Neuberg D, Bahar AY, Chapuy B, Kutok JL, Longtine JA, Kuo FC, Haley T, Salois M, Sullivan TJ, Fisher DC, Fox EA, Rodig SJ, Antin JH and Weinstock DM (2012). Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation. Cancer Discovery, 2, 47-55.

Weigert O, Lane AA, Bird L, Kopp N, Chapuy B, van Bodegom D, Toms AV, Marubayashi S, Christie AL, McKeown M, Paranal RM, Bradner JE, Yoda A, Gaul C, Vangrevelinghe E, Romanet V, Murakami M, Tiedt R, Ebel N, Evrot E, De Pover A, Régnier CH, Erdmann D, Hofmann F, Eck MJ, Sallan SE, Levine RL, Kung AL, Baffert F, Radimerski T and Weinstock DM (2012). Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J Exp Med., 209, 259-273.

Weigert O and Weinstock DM (2012). The evolving contribution of hematopoietic progenitor cells to lymphomagenesis. Blood, 120, 2553-2561.

Weigert O, Weidmann E, Mueck R, Bentz M, von Schilling C, Rohrberg R, Jentsch-Ullrich K, Hiddemann W and Dreyling M (2009). A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma – long-term results of a multicenter observation study. Leuk Lymphoma, 50, 716-722.

Weigert O, Pastore A, Rieken M, Lang N, Hiddemann W and Dreyling M (2007). Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma. Leukemia, 21, 524-528.